The Role of Gut Microbiota in Tumor Immunotherapy DOI Creative Commons
Miao Wu, Jiawei Bai, Chengtai Ma

et al.

Journal of Immunology Research, Journal Year: 2021, Volume and Issue: 2021, P. 1 - 12

Published: Aug. 26, 2021

Tumor immunotherapy is the fourth therapy after surgery, chemotherapy, and radiotherapy. It has made great breakthroughs in treatment of some epithelial tumors hematological tumors. However, its adverse reactions are common or even more serious, response rate solid not satisfactory. With maturity genomics metabolomics technologies, effect intestinal microbiota tumor development gradually been recognized. The may affect immunity by regulating host immune system microenvironment. Some bacteria help fight activating immunity, while mediate immunosuppression to cancer cells escape from system. More studies have revealed that effects complications related composition gut microbiota. sensitive prone certain characteristics. These characteristics be used as biomarkers predict prognosis also developed “immune potentiators” assist immunotherapy. clinical preclinical proved microbial intervention, including transplantation, can improve sensitivity reduce a extent. gene editing technology nanotechnology, design engineered contribute become new research hotspot. Based on relationship between immunotherapy, correct mining information reasonable feasible intervention methods expected optimize large extent bring treatment.

Language: Английский

Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments DOI Creative Commons
Zhennan Yuan, Yingpu Li, Sifan Zhang

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: March 11, 2023

The malignant tumor is a multi-etiological, systemic and complex disease characterized by uncontrolled cell proliferation distant metastasis. Anticancer treatments including adjuvant therapies targeted are effective in eliminating cancer cells but limited number of patients. Increasing evidence suggests that the extracellular matrix (ECM) plays an important role development through changes macromolecule components, degradation enzymes stiffness. These variations under control cellular components tissue via aberrant activation signaling pathways, interaction ECM to multiple surface receptors, mechanical impact. Additionally, shaped regulates immune which results suppressive microenvironment hinders efficacy immunotherapies. Thus, acts as barrier protect from supports progression. Nevertheless, profound regulatory network remodeling hampers design individualized antitumor treatment. Here, we elaborate on composition ECM, discuss specific mechanisms remodeling. Precisely, highlight impact development, proliferation, anoikis, metastasis, angiogenesis, lymphangiogenesis, escape. Finally, emphasize "normalization" potential strategy for anti-malignant

Language: Английский

Citations

368
Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy DOI Open Access
Miljana Nenkov, Yunxia Ma,

Nikolaus Gaßler

et al.

International Journal of Molecular Sciences, Journal Year: 2021, Volume and Issue: 22(12), P. 6262 - 6262

Published: June 10, 2021

Colorectal carcinoma (CRC) is one of the most frequently diagnosed carcinomas and leading causes cancer-related death worldwide. Metabolic reprogramming, a hallmark cancer, closely related to initiation progression carcinomas, including CRC. Accumulating evidence shows that activation oncogenic pathways loss tumor suppressor genes regulate metabolic reprogramming mainly involved in glycolysis, glutaminolysis, one-carbon metabolism lipid metabolism. The abnormal program provides cells with abundant energy, nutrients redox requirements support their malignant growth metastasis, which accompanied by impaired flexibility microenvironment (TME) dysbiosis gut microbiota. crosstalk between cells, components TME intestinal microbiota further facilitates CRC cell proliferation, invasion metastasis leads therapy resistance. Hence, target dysregulated metabolism, microbiota, novel preventive therapeutic applications are required. In this review, dysregulation programs, molecular pathways, addressed. Possible strategies, inhibition immune CRC, as well modulation aberrant discussed.

Language: Английский

Citations

106
A Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy DOI Creative Commons
Qiqing Yang, Bin Wang, Qinghui Zheng

et al.

Advanced Science, Journal Year: 2023, Volume and Issue: 10(15)

Published: March 23, 2023

Abstract Gut microbiota‐derived metabolites are key hubs connecting the gut microbiome and cancer progression, primarily by remodeling tumor microenvironment regulating signaling pathways in cells multiple immune cells. The use of microbial radiotherapy chemotherapy mitigates severe side effects from treatment improves efficacy treatment. Immunotherapy combined with effectively activates system to kill tumors overcomes drug resistance. Consequently, various novel strategies have been developed modulate metabolites. Manipulation genes involved metabolism using synthetic biology approaches directly affects levels metabolites, while fecal transplantation phage affect altering composition microbiome. However, some harbor paradoxical functions depending on context (e.g., type cancer). Furthermore, metabolic microorganisms certain anticancer drugs such as irinotecan gemcitabine, render ineffective or exacerbate their adverse effects. Therefore, a personalized comprehensive consideration patient's condition is required when employing treat cancer. purpose this review summarize correlation between cancer, provide fresh ideas for future scientific research.

Language: Английский

Citations

99
Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives DOI Creative Commons

Sawsan Sudqi Said,

Wisam Nabeel Ibrahim

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(4), P. 1143 - 1143

Published: April 4, 2023

Cancer immunotherapy is a type of treatment that harnesses the power immune systems patients to target cancer cells with better precision compared traditional chemotherapy. Several lines have been approved by US Food and Drug Administration (FDA) led remarkable success in solid tumors, such as melanoma small-cell lung cancer. These immunotherapies include checkpoint inhibitors, cytokines, vaccines, while chimeric antigen receptor (CAR) T-cell has shown responses hematological malignancies. Despite these breakthrough achievements, response variable among patients, only small percentage gained from this treatment, depending on histological tumor other host factors. develop mechanisms avoid interacting circumstances, which an adverse effect how effectively they react therapy. arise either due intrinsic factors within or microenvironment (TME). When scenario used therapeutic setting, term “resistance immunotherapy” applied; “primary resistance” denotes failure respond start, “secondary relapse following initial immunotherapy. Here, we provide thorough summary internal external underlying resistance Furthermore, variety are briefly discussed, along recent developments employed prevent relapses focus upcoming initiatives improve efficacy for patients.

Language: Английский

Citations

52
Resistance mechanisms to immune checkpoint inhibitors: updated insights DOI Creative Commons

Besan H. Al-Saafeen,

Bassam R. Ali, Eyad Elkord

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: Jan. 15, 2025

The last decade has witnessed unprecedented succusses with the use of immune checkpoint inhibitors in treating cancer. Nevertheless, proportion patients who respond favorably to treatment remained rather modest, partially due resistance. This fueled a wave research into potential mechanisms resistance which can be classified primary or acquired after an initial response. In current review, we summarize what is known so far about terms being tumor-intrinsic tumor-extrinsic taking account multimodal crosstalk between tumor, system compartment and other host-related factors.

Language: Английский

Citations

3
Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies DOI Creative Commons

D.Y. Luo,

Jing Zhou, Shuiliang Ruan

et al.

Cell Death and Disease, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 7, 2025

Abstract Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, with limited treatment options in advanced stages. Immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting PD1/PD-L1, has emerged as promising therapeutic approach. However, significant proportion patients exhibit primary or acquired resistance, limiting the overall efficacy immunotherapy. This review provides comprehensive analysis mechanisms underlying immunotherapy resistance GC, including role tumor microenvironment, dynamic PD-L1 expression, compensatory activation other checkpoints, and genomic instability. Furthermore, explores GC-specific factors such molecular subtypes, unique evasion mechanisms, impact Helicobacter pylori infection. We also discuss emerging strategies to overcome combination therapies, novel immunotherapeutic approaches, personalized based on genomics microenvironment. By highlighting these key areas, this aims inform future research directions clinical practice, ultimately improving outcomes for GC undergoing

Language: Английский

Citations

2
Microbiota and prostate cancer DOI
Alessandro Rizzo, Matteo Santoni, Veronica Mollica

et al.

Seminars in Cancer Biology, Journal Year: 2021, Volume and Issue: 86, P. 1058 - 1065

Published: Sept. 15, 2021

Language: Английский

Citations

69
Alginate/κ-carrageenan oral microcapsules loaded with Agaricus bisporus polysaccharides MH751906 for natural killer cells mediated colon cancer immunotherapy DOI
Nehal M. El‐Deeb, Omar M. Ibrahim, Mahmoud A. Mohamed

et al.

International Journal of Biological Macromolecules, Journal Year: 2022, Volume and Issue: 205, P. 385 - 395

Published: Feb. 17, 2022

Language: Английский

Citations

60
Inflammasome signaling in colorectal cancer DOI Creative Commons
Bhesh Raj Sharma, Thirumala‐Devi Kanneganti

Translational research, Journal Year: 2022, Volume and Issue: 252, P. 45 - 52

Published: Sept. 21, 2022

Language: Английский

Citations

55
Mucosal-associated invariant T cells for cancer immunotherapy DOI Creative Commons
Yan-Ruide Li, Kuangyi Zhou, Matthew Wilson

et al.

Molecular Therapy, Journal Year: 2022, Volume and Issue: 31(3), P. 631 - 646

Published: Dec. 5, 2022

Human mucosal-associated invariant T (MAIT) cells are characterized by their expression of an TCR α chain Vα7.2-Jα33/Jα20/Jα12 paired with a restricted β chain. MAIT recognize microbial peptides presented the highly conserved MHC class I-like molecule MR1 and bridge innate acquired immune systems to mediate augmented responses. Upon activation, rapidly proliferate, produce variety cytokines cytotoxic molecules, trigger efficient antitumor immunity. Administration representative cell ligand 5-OP-RU effectively activates enhances capacity. In this review, we introduce biology importance in immunity, summarize current development peripheral blood mononuclear cell-derived stem products for cancer treatment, discuss potential genetic engineering off-the-shelf immunotherapy.

Language: Английский

Citations

43